{"props":{"pageProps":{"readerId":"440d4fc9-023c-57f9-8e66-c849e41f96b5","contactId":"","pageUrl":"https://www.economist.com/leaders/2024/03/07/a-frenzy-of-innovation-in-obesity-drugs-is-under-way","domain":"https://www.economist.com","auth":{"loggedIn":true,"verified":false,"isAnonymous":true,"isSubscriber":false,"bulkSubscriber":false,"userType":"anonymous"},"pageType":"ARTICLE","isSubscriber":false,"region":"US","content":{"url":{"canonical":"https://www.economist.com/leaders/2024/03/07/a-frenzy-of-innovation-in-obesity-drugs-is-under-way","__typename":"URL"},"__typename":"Content","id":"/content/1um6f1d5i4t6deldkd9ma4gql52ftfa2","tegID":"1um6f1d5i4t6deldkd9ma4gql52ftfa2","type":["Article","NewsArticle","AnalysisNewsArticle"],"headline":"A frenzy of innovation in obesity drugs is under way","subheadline":"The real skinny","seoPageTitle":null,"seoMetadataDescription":null,"ad":{"grapeshot":{"channels":[{"name":"gv_safe","score":28217.996,"__typename":"GrapeshotChannel"},{"name":"gb_safe","score":4.986,"__typename":"GrapeshotChannel"},{"name":"gb_safe_from_high","score":4.986,"__typename":"GrapeshotChannel"},{"name":"gb_safe_from_high_med","score":4.986,"__typename":"GrapeshotChannel"},{"name":"pos_israel-hamas_war","score":4.986,"__typename":"GrapeshotChannel"},{"name":"gs_busfin","score":4.976,"__typename":"GrapeshotChannel"},{"name":"gs_health","score":4.846,"__typename":"GrapeshotChannel"},{"name":"neg_goldmansachs_brandsafety","score":4.846,"__typename":"GrapeshotChannel"},{"name":"healthcare_related_topics","score":4.844,"__typename":"GrapeshotChannel"},{"name":"chanel_neg","score":3.252,"__typename":"GrapeshotChannel"},{"name":"gs_health_misc","score":3.208,"__typename":"GrapeshotChannel"},{"name":"gs_busfin_indus","score":2.53,"__typename":"GrapeshotChannel"},{"name":"neg_omd_exclusion","score":2.304,"__typename":"GrapeshotChannel"},{"name":"future_of_work_test","score":2.191,"__typename":"GrapeshotChannel"},{"name":"neg_exxon","score":2.135,"__typename":"GrapeshotChannel"},{"name":"gs_healthylvng","score":2.068,"__typename":"GrapeshotChannel"},{"name":"healthcare","score":1.983,"__typename":"GrapeshotChannel"},{"name":"america_department_commerce","score":1.942,"__typename":"GrapeshotChannel"},{"name":"gs_business","score":1.867,"__typename":"GrapeshotChannel"},{"name":"neg_dit4","score":1.778,"__typename":"GrapeshotChannel"},{"name":"test","score":1.762,"__typename":"GrapeshotChannel"},{"name":"ibm_blacklist","score":1.663,"__typename":"GrapeshotChannel"},{"name":"neg_fidelity_gmo","score":1.618,"__typename":"GrapeshotChannel"},{"name":"gs_busfin_economy","score":1.574,"__typename":"GrapeshotChannel"},{"name":"ssga_currency_wars","score":1.532,"__typename":"GrapeshotChannel"},{"name":"fow_barclays","score":1.408,"__typename":"GrapeshotChannel"},{"name":"cigna_healthyhybridworkplace","score":1.389,"__typename":"GrapeshotChannel"},{"name":"neg_3166_vca_brand-safety","score":1.375,"__typename":"GrapeshotChannel"},{"name":"america_department_health","score":1.367,"__typename":"GrapeshotChannel"},{"name":"gs_health_weightloss","score":1.347,"__typename":"GrapeshotChannel"},{"name":"gs_healthylvng_weightloss","score":1.347,"__typename":"GrapeshotChannel"},{"name":"neg_workday_master","score":1.324,"__typename":"GrapeshotChannel"},{"name":"microsoft_blacklist","score":1.312,"__typename":"GrapeshotChannel"},{"name":"gs_economy","score":1.241,"__typename":"GrapeshotChannel"},{"name":"neg_jpm_2024q4","score":1.166,"__typename":"GrapeshotChannel"},{"name":"gt_mixed","score":1.165,"__typename":"GrapeshotChannel"},{"name":"business_startup","score":1.139,"__typename":"GrapeshotChannel"},{"name":"neg_3166_vca_brand-safety3","score":1.134,"__typename":"GrapeshotChannel"},{"name":"gs_tech","score":1.09,"__typename":"GrapeshotChannel"},{"name":"neg_dit","score":1.085,"__typename":"GrapeshotChannel"},{"name":"future_of_work","score":1.079,"__typename":"GrapeshotChannel"},{"name":"barclays_contextual_targets_2022-08-22","score":1.029,"__typename":"GrapeshotChannel"},{"name":"ssga_infrastructure","score":1.024,"__typename":"GrapeshotChannel"},{"name":"gs_busfin_economy_markets","score":1.014,"__typename":"GrapeshotChannel"},{"name":"gs_economy_markets","score":1.014,"__typename":"GrapeshotChannel"},{"name":"artificial_intelligence","score":0.989,"__typename":"GrapeshotChannel"},{"name":"america_medicare","score":0.982,"__typename":"GrapeshotChannel"},{"name":"ts_tech","score":0.916,"__typename":"GrapeshotChannel"},{"name":"fidelity_blacklist","score":0.893,"__typename":"GrapeshotChannel"},{"name":"universal_negative_keywords","score":0.891,"__typename":"GrapeshotChannel"},{"name":"cigna_puttingfamilyfirst","score":0.872,"__typename":"GrapeshotChannel"},{"name":"gs_busfin_business","score":0.871,"__typename":"GrapeshotChannel"},{"name":"ibm_tech_2020","score":0.862,"__typename":"GrapeshotChannel"}],"__typename":"Grapeshot"},"__typename":"Ad"},"audio":{"main":{"url":{"canonical":"https://www.economist.com/media-assets/audio/008%20Leaders%20-%20Obesity%20drugs-b9ee17c61a6793a9fecfeccf5e56555a.mp3","__typename":"URL"},"__typename":"Content","duration":"5:16","hasPart":{"parts":[{"podcastLocked":false,"headline":"A frenzy of innovation in obesity drugs is under way","datePublished":"2024-03-07T14:15:46Z","publication":[{"type":["PublicationIssue"],"headline":"WEEKLY EDITION: MAR 9TH 2024","podcastImage":"","keyword":[],"podcastSlug":"","__typename":"Content"},{"type":["PublicationIssue","RegionalIssue"],"headline":"WEEKLY EDITION: MAR 9TH 2024","podcastImage":"","keyword":[],"podcastSlug":"","__typename":"Content"},{"type":["PublicationIssue","RegionalIssue"],"headline":"WEEKLY EDITION: MAR 9TH 2024","podcastImage":"","keyword":[],"podcastSlug":"","__typename":"Content"},{"type":["PublicationIssue","RegionalIssue"],"headline":"WEEKLY EDITION: MAR 9TH 2024","podcastImage":"","keyword":[],"podcastSlug":"","__typename":"Content"},{"type":["PublicationIssue","RegionalIssue"],"headline":"WEEKLY EDITION: MAR 9TH 2024","podcastImage":"","keyword":[],"podcastSlug":"","__typename":"Content"},{"type":["PublicationIssue","RegionalIssue"],"headline":"WEEKLY EDITION: MAR 9TH 2024","podcastImage":"","keyword":[],"podcastSlug":"","__typename":"Content"},{"type":["PublicationIssue","RegionalIssue"],"headline":"WEEKLY EDITION: MAR 9TH 2024","podcastImage":"","keyword":[],"podcastSlug":"","__typename":"Content"},{"type":["PublicationIssue","RegionalIssue"],"headline":"WEEKLY EDITION: MAR 9TH 2024","podcastImage":"","keyword":[],"podcastSlug":"","__typename":"Content"}],"__typename":"Content"}],"__typename":"HasPart"}},"__typename":"Media"},"image":{"main":{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_LDD002.jpg","__typename":"URL"},"__typename":"Content","height":720,"width":1280,"description":""},"promo":null,"__typename":"Media"},"description":"Novo Nordisk and Eli Lilly are printing money now. But they will not be a stagnant duopoly","datePublished":"2024-03-07T14:15:46Z","dateModified":"2024-03-07T22:29:27Z","dateRevised":"","dateRevisedString":"","datePublishedString":"Mar 7th 2024","dateCreated":"2024-03-06T11:41:55Z","copyrightYear":2024,"inLanguage":"en","byline":"","dateline":null,"topic":null,"text":[{"type":"tag","name":"p","attribs":{},"children":[{"type":"tag","name":"span","attribs":{"data-caps":"initial"},"children":[{"data":"W","type":"text"}]},{"type":"tag","name":"small","attribs":{},"children":[{"data":"eight-loss jabs","type":"text"}]},{"data":" have turned out to be blockbusters. And for good reason. For one thing, after centuries of false promises and quackery, these drugs actually work. With nearly half the world’s population expected to be obese or overweight by 2030, demand for them is assured. And, more excitingly, they may be approved for a broader set of uses. Clinical trials suggest that they could reduce the risk of heart attacks, kidney disease and perhaps even Alzheimer’s. By the end of the decade ","type":"text"},{"type":"tag","name":"a","attribs":{"href":"https://www.economist.com/business/2024/03/04/the-battle-over-the-trillion-dollar-weight-loss-bonanza","data-tegid":"t8uh7o9kvdcvhs10ldnfabria96scp5e"},"children":[{"data":"annual sales of obesity medicines","type":"text"}]},{"data":" could hit $80bn, making them one of pharma’s biggest classes of drugs. ","type":"text"}]},{"type":"tag","name":"p","attribs":{},"children":[{"data":"No wonder enthusiasm for the makers of these drugs, Novo Nordisk and Eli Lilly, is at fever pitch. Since the start of 2023 Novo, maker of Wegovy (and its sibling Ozempic), has seen its market capitalisation soar by 87% to $560bn, making it Europe’s most valuable company. Meanwhile the market value of Lilly, maker of Zepbound (and its sibling Mounjaro), has more than doubled to $740bn. One of these drugmakers could be the first to attain a market value of a trillion dollars, joining an elite club mostly made up of tech firms. ","type":"text"}]},{"type":"tag","name":"figure","attribs":{"itemtype":"https://schema.org/ImageObject"},"children":[{"type":"tag","name":"img","attribs":{"src":"https://www.economist.com/media-assets/image/20240309_LDC677.png","data-teg-id":"73vl5rdjo4pcj5orcg2ttb8ktmiqpqdq","data-slim":"1","height":"662","width":"608"},"children":[]}]},{"type":"tag","name":"p","attribs":{},"children":[{"data":"Add in the limited volumes and high prices for these drugs today, and you might think that this nascent industry is on course to be a price-gouging duopoly. In fact, the market will soon look drastically different from what you see now. ","type":"text"}]},{"type":"tag","name":"p","attribs":{},"children":[{"data":"Right now the drugs are in short supply. Shortages of their active ingredients, like semaglutide for Wegovy, and of the skinny “pens” used to inject the medicine, are a constraint on production. And with a list price of almost $16,000 a year, these treatments are not cheap. Although a few users may be able to afford the cost themselves, most will need help from insurers or health services—many of which have yet to be convinced that the benefits are worth the drugs’ eye-watering prices. ","type":"text"}]},{"type":"tag","name":"p","attribs":{},"children":[{"data":"Access will be an even bigger problem in much of the emerging world, which is projected to experience the largest increases in obesity as incomes rise and diets change. So far most of Lilly’s and Novo’s sales have been in America, with the rest going mainly to Europe. Nor does it help emerging-world patients that the jabs need to be refrigerated, making them unsuitable for use in countries with less developed supply chains.","type":"text"}]},{"type":"tag","name":"p","attribs":{},"children":[{"data":"Yet there are good reasons to think that in future the market will see expanded supply, lower prices and a more global patient base. For a start, investment by Lilly and Novo to expand production should ease bottlenecks over time. Both firms are pouring billions of dollars into boosting supply by building their own capacity and teaming up with other manufacturers. Lilly and Novo are also racing to gain an edge over each other. Novo has already developed a pill that is about as effective as its injectable version. Lilly expects to launch its own obesity pill in a few years. Both companies also have newer versions of the drugs in the late stages of development which are more efficacious or have fewer side-effects. ","type":"text"}]},{"type":"tag","name":"p","attribs":{},"children":[{"data":"More important in the long term, however, is the array of competitors preparing to enter the market. Wegovy, Zepbound and their ilk are less protected by patents than, say, Humira, a blockbuster anti-inflammatory drug that has reaped more than $200bn in sales over 20 years. ","type":"text"}]},{"type":"tag","name":"p","attribs":{},"children":[{"data":"Already more than 70 companies are running close to 100 clinical trials for obesity drugs. These include big pharma firms (Amgen and Boehringer Ingelheim) and smaller biotechs (Viking Therapeutics and Structure Therapeutics) in the West, as well as Chinese drugmakers such as Sciwind Biosciences and Eccogene. Many are testing versions that are distinct enough from Wegovy and Zepbound that patent protections will not apply, allowing them to come to market within a few years, should they gain regulators’ blessing. ","type":"text"}]},{"type":"tag","name":"p","attribs":{},"children":[{"data":"Some candidates in the pipeline could be more effective than existing treatments; others might do away with the inconvenience of today’s drugs, which require patients to inject themselves once a week and to continue taking them indefinitely to keep their weight down. Viking’s experimental drug, for example, has been shown to help patients shed more weight than existing jabs. Amgen is testing a treatment that does not require patients to be on the drugs indefinitely. And Structure is developing a promising-looking pill.","type":"text"}]},{"type":"tag","name":"h2","attribs":{},"children":[{"data":"Healthy competition ","type":"text"}]},{"type":"tag","name":"p","attribs":{},"children":[{"data":"This frenzy of innovation is welcome. Lilly and Novo may lose their lead in the long term if cheaper alternatives arise; or they may themselves furiously innovate to reduce costs. Either way, prices should come down, making the drugs more accessible to patients around the world. Today the two pharma firms are reaping the rewards from their blockbuster drugs. But in time it will be consumers who benefit most of all. ","type":"text"},{"type":"tag","name":"span","attribs":{"data-ornament":"ufinish"},"children":[{"data":"■","type":"text"}]}]}],"about":{"public":null,"__typename":"Taxonomies"},"print":{"headline":"The real skinny","section":{"url":{"canonical":"https://www.economist.com/leaders/","__typename":"URL"},"__typename":"Content","headline":"Leaders"},"__typename":"Print"},"contentIdentity":{"articleType":null,"mediaType":null,"__typename":"ContentIdentity"},"articleSection":{"public":null,"internal":[{"url":{"canonical":"https://www.economist.com/leaders/","__typename":"URL"},"__typename":"Content","id":"/content/0eqdc3kshoq96naup34ruco7pktc6n51","tegID":"0eqdc3kshoq96naup34ruco7pktc6n51","headline":"Leaders","hasPart":{"parts":[{"url":{"canonical":"https://www.economist.com/leaders/2024/03/07/how-to-fix-the-ivy-league","__typename":"URL"},"__typename":"Content","id":"/content/qpdv8eb2h88475llth416pofo57og2sp","type":["Article","NewsArticle","AnalysisNewsArticle"],"contentIdentity":{"mediaType":null,"articleType":null,"__typename":"ContentIdentity"},"articleSection":{"internal":[{"url":{"canonical":"https://www.economist.com/leaders/","__typename":"URL"},"__typename":"Content","headline":"Leaders","tegID":"0eqdc3kshoq96naup34ruco7pktc6n51"}],"__typename":"Taxonomies"},"publication":[{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"ndld7fhnv12a94rdb4elsi90p935h1jf"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/eu/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"23j7i6b019gq99n60p77r1k56hm0jp0c"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/ap/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"lvqsf1s86hc9obrhctvrb0d68a5377d7"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/la/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"s91ah9uegdq8v3q1i78ohfu88ntmculi"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/me/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"3so95mfk1putcqd9uf6offvhoba3k29e"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/uk/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"dvsjeap731lsv61lg7oj3fpol5pb2ujh"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/na/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"9fe6gsio9nuviqsqgonkikgss6mv5g6s"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/a/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"b415k2h5cui7fcns2kuk381p7cr00si3"}],"channel":{"tegID":"j53t6hsedat4l7rkbb1le98u73262sh5","__typename":"Content"},"headline":"How to fix the Ivy League","subheadline":"Course correction","datePublished":"2024-03-07T14:15:50Z","description":"Its supremacy is being undermined by bad leadership","image":{"main":{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_LDP001.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":720},"__typename":"Media","promo":null}},{"url":{"canonical":"https://www.economist.com/leaders/2024/03/07/a-frenzy-of-innovation-in-obesity-drugs-is-under-way","__typename":"URL"},"__typename":"Content","id":"/content/1um6f1d5i4t6deldkd9ma4gql52ftfa2","type":["Article","NewsArticle","AnalysisNewsArticle"],"contentIdentity":{"mediaType":null,"articleType":null,"__typename":"ContentIdentity"},"articleSection":{"internal":[{"url":{"canonical":"https://www.economist.com/leaders/","__typename":"URL"},"__typename":"Content","headline":"Leaders","tegID":"0eqdc3kshoq96naup34ruco7pktc6n51"}],"__typename":"Taxonomies"},"publication":[{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"ndld7fhnv12a94rdb4elsi90p935h1jf"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/eu/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"23j7i6b019gq99n60p77r1k56hm0jp0c"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/ap/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"lvqsf1s86hc9obrhctvrb0d68a5377d7"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/la/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"s91ah9uegdq8v3q1i78ohfu88ntmculi"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/me/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"3so95mfk1putcqd9uf6offvhoba3k29e"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/uk/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"dvsjeap731lsv61lg7oj3fpol5pb2ujh"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/na/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"9fe6gsio9nuviqsqgonkikgss6mv5g6s"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/a/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"b415k2h5cui7fcns2kuk381p7cr00si3"}],"channel":{"tegID":"j53t6hsedat4l7rkbb1le98u73262sh5","__typename":"Content"},"headline":"A frenzy of innovation in obesity drugs is under way","subheadline":"The real skinny","datePublished":"2024-03-07T14:15:46Z","description":"Novo Nordisk and Eli Lilly are printing money now. But they will not be a stagnant duopoly","image":{"main":{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_LDD002.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":720},"__typename":"Media","promo":null}},{"url":{"canonical":"https://www.economist.com/leaders/2024/03/07/three-big-risks-that-might-tip-americas-presidential-election","__typename":"URL"},"__typename":"Content","id":"/content/pjnov0aulirars6bj94fb8g53tp82r7n","type":["Article","NewsArticle","AnalysisNewsArticle"],"contentIdentity":{"mediaType":null,"articleType":null,"__typename":"ContentIdentity"},"articleSection":{"internal":[{"url":{"canonical":"https://www.economist.com/leaders/","__typename":"URL"},"__typename":"Content","headline":"Leaders","tegID":"0eqdc3kshoq96naup34ruco7pktc6n51"}],"__typename":"Taxonomies"},"publication":[{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"ndld7fhnv12a94rdb4elsi90p935h1jf"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/eu/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"23j7i6b019gq99n60p77r1k56hm0jp0c"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/ap/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"lvqsf1s86hc9obrhctvrb0d68a5377d7"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/la/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"s91ah9uegdq8v3q1i78ohfu88ntmculi"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/me/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"3so95mfk1putcqd9uf6offvhoba3k29e"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/uk/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"dvsjeap731lsv61lg7oj3fpol5pb2ujh"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/na/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"9fe6gsio9nuviqsqgonkikgss6mv5g6s"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/a/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"b415k2h5cui7fcns2kuk381p7cr00si3"}],"channel":{"tegID":"j53t6hsedat4l7rkbb1le98u73262sh5","__typename":"Content"},"headline":"Three big risks that might tip America’s presidential election","subheadline":"And they’re off","datePublished":"2024-03-07T10:18:00Z","description":"Third parties, the Trump trials and the candidates’ age introduce a high degree of uncertainty","image":{"main":{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_LDD001_FH.jpg","__typename":"URL"},"__typename":"Content","width":1080,"height":1200},"__typename":"Media","promo":{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_LDD001.jpg","__typename":"URL"},"__typename":"Content","height":720,"width":1280}}},{"url":{"canonical":"https://www.economist.com/leaders/2024/03/06/britains-budget-cuts-taxes-on-the-promise-of-productivity-gains","__typename":"URL"},"__typename":"Content","id":"/content/qj3dgelcejlfm5ridms4lr472s6fgb05","type":["Article","NewsArticle","AnalysisNewsArticle"],"contentIdentity":{"mediaType":null,"articleType":null,"__typename":"ContentIdentity"},"articleSection":{"internal":[{"url":{"canonical":"https://www.economist.com/leaders/","__typename":"URL"},"__typename":"Content","headline":"Leaders","tegID":"0eqdc3kshoq96naup34ruco7pktc6n51"}],"__typename":"Taxonomies"},"publication":[{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"ndld7fhnv12a94rdb4elsi90p935h1jf"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/eu/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"23j7i6b019gq99n60p77r1k56hm0jp0c"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/ap/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"lvqsf1s86hc9obrhctvrb0d68a5377d7"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/la/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"s91ah9uegdq8v3q1i78ohfu88ntmculi"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/me/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"3so95mfk1putcqd9uf6offvhoba3k29e"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/uk/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"dvsjeap731lsv61lg7oj3fpol5pb2ujh"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/na/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"9fe6gsio9nuviqsqgonkikgss6mv5g6s"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/a/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"b415k2h5cui7fcns2kuk381p7cr00si3"}],"channel":{"tegID":"j53t6hsedat4l7rkbb1le98u73262sh5","__typename":"Content"},"headline":"Britain’s budget cuts taxes on the promise of productivity gains","subheadline":"Jam today, ingredients tomorrow","datePublished":"2024-03-06T20:48:19Z","description":"Jeremy Hunt has got it the wrong way round","image":{"main":{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_LDP503.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":720},"__typename":"Media","promo":null}},{"url":{"canonical":"https://www.economist.com/leaders/2024/03/06/xi-jinpings-hunger-for-power-is-hurting-chinas-economy","__typename":"URL"},"__typename":"Content","id":"/content/3r4cv269l8u8p03hed3lhvfa9c61ata9","type":["Article","NewsArticle","AnalysisNewsArticle"],"contentIdentity":{"mediaType":null,"articleType":null,"__typename":"ContentIdentity"},"articleSection":{"internal":[{"url":{"canonical":"https://www.economist.com/leaders/","__typename":"URL"},"__typename":"Content","headline":"Leaders","tegID":"0eqdc3kshoq96naup34ruco7pktc6n51"}],"__typename":"Taxonomies"},"publication":[{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"ndld7fhnv12a94rdb4elsi90p935h1jf"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/eu/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"23j7i6b019gq99n60p77r1k56hm0jp0c"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/ap/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"lvqsf1s86hc9obrhctvrb0d68a5377d7"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/la/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"s91ah9uegdq8v3q1i78ohfu88ntmculi"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/me/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"3so95mfk1putcqd9uf6offvhoba3k29e"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/uk/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"dvsjeap731lsv61lg7oj3fpol5pb2ujh"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/na/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"9fe6gsio9nuviqsqgonkikgss6mv5g6s"},{"headline":"WEEKLY EDITION: MAR 9TH 2024","url":{"canonical":"https://www.economist.com/a/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","tegID":"b415k2h5cui7fcns2kuk381p7cr00si3"}],"channel":{"tegID":"j53t6hsedat4l7rkbb1le98u73262sh5","__typename":"Content"},"headline":"Xi Jinping’s hunger for power is hurting China’s economy","subheadline":"China’s National People’s Congress","datePublished":"2024-03-06T09:51:14Z","description":"A new economic plan won’t end deflation, even as he sidelines his prime minister","image":{"main":{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_LDP002.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":720},"__typename":"Media","promo":null}}],"__typename":"HasPart"}}],"__typename":"Taxonomies"},"publication":[{"url":{"canonical":"https://www.economist.com/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","type":["PublicationIssue"],"headline":"WEEKLY EDITION: MAR 9TH 2024","description":"","subheadline":"","datePublished":"2024-03-09T00:00:00Z","datePublishedString":"Mar 9th 2024","id":"/content/ndld7fhnv12a94rdb4elsi90p935h1jf","tegID":"ndld7fhnv12a94rdb4elsi90p935h1jf","image":{"cover":[{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_US.jpg","__typename":"URL"},"__typename":"Content","headline":"And they’re off. What could upend America’s election?","width":1280,"height":1684,"regionsAllowed":["US","CA","PM","UM","AI","BL","BQ","BV","CW","GS","MF","SX","AG","AR","AW","BS","BB","BZ","BM","BO","BR","KY","CL","CO","CR","CU","DM","DO","EC","SV","FK","GF","GD","GP","GT","GY","HN","HT","JM","MQ","MX","MS","NI","PA","PY","PE","PR","KN","LC","VC","SR","TT","TC","UY","VE","VG","VI"]},{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_EU.jpg","__typename":"URL"},"__typename":"Content","headline":"And they’re off. What could upend America’s election?","width":1280,"height":1684,"regionsAllowed":["AD","AL","AM","AX","AZ","BA","BG","BY","CH","CY","CZ","EE","FO","GE","GI","GL","HR","HU","IS","KG","KZ","LI","LT","LV","MC","MD","ME","MK","MT","NO","PL","RO","RS","RU","SI","SJ","SK","SM","TJ","TM","TR","UA","UZ","VA","IT","FR","ES","IE","AT","BE","DK","FI","DE","GR","LU","NL","PT","SE","BH","IR","IQ","IL","JO","KW","LB","OM","SA","SY","AE","PS","QA","YE","DZ","AO","BJ","BW","BF","BI","CM","CV","CF","TD","KM","CD","CI","DJ","EG","GQ","ER","ET","GA","GM","GH","GN","GW","KE","LS","LR","LY","MG","MU","MW","ML","MR","YT","MA","MZ","NA","NE","NG","RE","RW","SH","SS","ST","SN","SL","SO","ZA","SD","SZ","TZ","TG","TN","UG","EH","ZM","ZW","CG"]},{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_AP.jpg","__typename":"URL"},"__typename":"Content","headline":"And they’re off. What could upend America’s election?","width":1280,"height":1684,"regionsAllowed":["AF","AS","AU","BD","BT","BN","KH","CN","CK","FJ","GU","PF","HK","IN","ID","JP","KI","KP","KR","LA","MO","MY","MV","MH","FM","MN","MM","NR","NP","NC","NZ","PK","PG","PH","PN","SC","SG","SB","LK","TF","TW","TH","TO","TV","VU","VN","IO","CC","TL","HM","NU","NF","MP","PW","WS","CX","TK","WF"]},{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_EU.jpg","__typename":"URL"},"__typename":"Content","headline":"And they’re off. What could upend America’s election?","width":1280,"height":1684,"regionsAllowed":["AD","AL","AM","AX","AZ","BA","BG","BY","CH","CY","CZ","EE","FO","GE","GI","GL","HR","HU","IS","KG","KZ","LI","LT","LV","MC","MD","ME","MK","MT","NO","PL","RO","RS","RU","SI","SJ","SK","SM","TJ","TM","TR","UA","UZ","VA","IT","FR","ES","IE","AT","BE","DK","FI","DE","GR","LU","NL","PT","SE","BH","IR","IQ","IL","JO","KW","LB","OM","SA","SY","AE","PS","QA","YE","DZ","AO","BJ","BW","BF","BI","CM","CV","CF","TD","KM","CD","CI","DJ","EG","GQ","ER","ET","GA","GM","GH","GN","GW","KE","LS","LR","LY","MG","MU","MW","ML","MR","YT","MA","MZ","NA","NE","NG","RE","RW","SH","SS","ST","SN","SL","SO","ZA","SD","SZ","TZ","TG","TN","UG","EH","ZM","ZW","CG"]},{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_UK.jpg","__typename":"URL"},"__typename":"Content","headline":"And they’re off. What could upend America’s election?","width":1280,"height":1684,"regionsAllowed":["UK","GB","GG","IM","JE"]},{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_EU.jpg","__typename":"URL"},"__typename":"Content","headline":"And they’re off. What could upend America’s election?","width":1280,"height":1684,"regionsAllowed":["AD","AL","AM","AX","AZ","BA","BG","BY","CH","CY","CZ","EE","FO","GE","GI","GL","HR","HU","IS","KG","KZ","LI","LT","LV","MC","MD","ME","MK","MT","NO","PL","RO","RS","RU","SI","SJ","SK","SM","TJ","TM","TR","UA","UZ","VA","IT","FR","ES","IE","AT","BE","DK","FI","DE","GR","LU","NL","PT","SE","BH","IR","IQ","IL","JO","KW","LB","OM","SA","SY","AE","PS","QA","YE","DZ","AO","BJ","BW","BF","BI","CM","CV","CF","TD","KM","CD","CI","DJ","EG","GQ","ER","ET","GA","GM","GH","GN","GW","KE","LS","LR","LY","MG","MU","MW","ML","MR","YT","MA","MZ","NA","NE","NG","RE","RW","SH","SS","ST","SN","SL","SO","ZA","SD","SZ","TZ","TG","TN","UG","EH","ZM","ZW","CG"]}],"main":{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_US.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1684},"squareCover":[{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_SQ_EU.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1280},{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_SQ_AP.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1280},{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_SQ_EU.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1280},{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_SQ_UK.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1280},{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_SQ_EU.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1280}],"__typename":"Media"}},{"url":{"canonical":"https://www.economist.com/eu/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","type":["PublicationIssue","RegionalIssue"],"headline":"WEEKLY EDITION: MAR 9TH 2024","description":"","subheadline":"","datePublished":"2024-03-09T00:00:00Z","datePublishedString":"Mar 9th 2024","id":"/content/23j7i6b019gq99n60p77r1k56hm0jp0c","tegID":"23j7i6b019gq99n60p77r1k56hm0jp0c","image":{"cover":[{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_EU.jpg","__typename":"URL"},"__typename":"Content","headline":"And they’re off. What could upend America’s election?","width":1280,"height":1684,"regionsAllowed":["AD","AL","AM","AX","AZ","BA","BG","BY","CH","CY","CZ","EE","FO","GE","GI","GL","HR","HU","IS","KG","KZ","LI","LT","LV","MC","MD","ME","MK","MT","NO","PL","RO","RS","RU","SI","SJ","SK","SM","TJ","TM","TR","UA","UZ","VA","IT","FR","ES","IE","AT","BE","DK","FI","DE","GR","LU","NL","PT","SE","BH","IR","IQ","IL","JO","KW","LB","OM","SA","SY","AE","PS","QA","YE","DZ","AO","BJ","BW","BF","BI","CM","CV","CF","TD","KM","CD","CI","DJ","EG","GQ","ER","ET","GA","GM","GH","GN","GW","KE","LS","LR","LY","MG","MU","MW","ML","MR","YT","MA","MZ","NA","NE","NG","RE","RW","SH","SS","ST","SN","SL","SO","ZA","SD","SZ","TZ","TG","TN","UG","EH","ZM","ZW","CG"]}],"main":{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_EU.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1684},"squareCover":[{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_SQ_EU.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1280}],"__typename":"Media"}},{"url":{"canonical":"https://www.economist.com/ap/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","type":["PublicationIssue","RegionalIssue"],"headline":"WEEKLY EDITION: MAR 9TH 2024","description":"","subheadline":"","datePublished":"2024-03-09T00:00:00Z","datePublishedString":"Mar 9th 2024","id":"/content/lvqsf1s86hc9obrhctvrb0d68a5377d7","tegID":"lvqsf1s86hc9obrhctvrb0d68a5377d7","image":{"cover":[{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_AP.jpg","__typename":"URL"},"__typename":"Content","headline":"And they’re off. What could upend America’s election?","width":1280,"height":1684,"regionsAllowed":["AF","AS","AU","BD","BT","BN","KH","CN","CK","FJ","GU","PF","HK","IN","ID","JP","KI","KP","KR","LA","MO","MY","MV","MH","FM","MN","MM","NR","NP","NC","NZ","PK","PG","PH","PN","SC","SG","SB","LK","TF","TW","TH","TO","TV","VU","VN","IO","CC","TL","HM","NU","NF","MP","PW","WS","CX","TK","WF"]}],"main":{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_AP.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1684},"squareCover":[{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_SQ_AP.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1280}],"__typename":"Media"}},{"url":{"canonical":"https://www.economist.com/la/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","type":["PublicationIssue","RegionalIssue"],"headline":"WEEKLY EDITION: MAR 9TH 2024","description":"","subheadline":"","datePublished":"2024-03-09T00:00:00Z","datePublishedString":"Mar 9th 2024","id":"/content/s91ah9uegdq8v3q1i78ohfu88ntmculi","tegID":"s91ah9uegdq8v3q1i78ohfu88ntmculi","image":{"cover":[{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_US.jpg","__typename":"URL"},"__typename":"Content","headline":"And they’re off. What could upend America’s election?","width":1280,"height":1684,"regionsAllowed":["US","CA","PM","UM","AI","BL","BQ","BV","CW","GS","MF","SX","AG","AR","AW","BS","BB","BZ","BM","BO","BR","KY","CL","CO","CR","CU","DM","DO","EC","SV","FK","GF","GD","GP","GT","GY","HN","HT","JM","MQ","MX","MS","NI","PA","PY","PE","PR","KN","LC","VC","SR","TT","TC","UY","VE","VG","VI"]}],"main":{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_US.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1684},"squareCover":[{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_SQ_US.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1280}],"__typename":"Media"}},{"url":{"canonical":"https://www.economist.com/me/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","type":["PublicationIssue","RegionalIssue"],"headline":"WEEKLY EDITION: MAR 9TH 2024","description":"","subheadline":"","datePublished":"2024-03-09T00:00:00Z","datePublishedString":"Mar 9th 2024","id":"/content/3so95mfk1putcqd9uf6offvhoba3k29e","tegID":"3so95mfk1putcqd9uf6offvhoba3k29e","image":{"cover":[{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_EU.jpg","__typename":"URL"},"__typename":"Content","headline":"And they’re off. What could upend America’s election?","width":1280,"height":1684,"regionsAllowed":["AD","AL","AM","AX","AZ","BA","BG","BY","CH","CY","CZ","EE","FO","GE","GI","GL","HR","HU","IS","KG","KZ","LI","LT","LV","MC","MD","ME","MK","MT","NO","PL","RO","RS","RU","SI","SJ","SK","SM","TJ","TM","TR","UA","UZ","VA","IT","FR","ES","IE","AT","BE","DK","FI","DE","GR","LU","NL","PT","SE","BH","IR","IQ","IL","JO","KW","LB","OM","SA","SY","AE","PS","QA","YE","DZ","AO","BJ","BW","BF","BI","CM","CV","CF","TD","KM","CD","CI","DJ","EG","GQ","ER","ET","GA","GM","GH","GN","GW","KE","LS","LR","LY","MG","MU","MW","ML","MR","YT","MA","MZ","NA","NE","NG","RE","RW","SH","SS","ST","SN","SL","SO","ZA","SD","SZ","TZ","TG","TN","UG","EH","ZM","ZW","CG"]}],"main":{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_EU.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1684},"squareCover":[{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_SQ_EU.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1280}],"__typename":"Media"}},{"url":{"canonical":"https://www.economist.com/uk/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","type":["PublicationIssue","RegionalIssue"],"headline":"WEEKLY EDITION: MAR 9TH 2024","description":"","subheadline":"","datePublished":"2024-03-09T00:00:00Z","datePublishedString":"Mar 9th 2024","id":"/content/dvsjeap731lsv61lg7oj3fpol5pb2ujh","tegID":"dvsjeap731lsv61lg7oj3fpol5pb2ujh","image":{"cover":[{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_UK.jpg","__typename":"URL"},"__typename":"Content","headline":"And they’re off. What could upend America’s election?","width":1280,"height":1684,"regionsAllowed":["UK","GB","GG","IM","JE"]}],"main":{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_UK.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1684},"squareCover":[{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_SQ_UK.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1280}],"__typename":"Media"}},{"url":{"canonical":"https://www.economist.com/na/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","type":["PublicationIssue","RegionalIssue"],"headline":"WEEKLY EDITION: MAR 9TH 2024","description":"","subheadline":"","datePublished":"2024-03-09T00:00:00Z","datePublishedString":"Mar 9th 2024","id":"/content/9fe6gsio9nuviqsqgonkikgss6mv5g6s","tegID":"9fe6gsio9nuviqsqgonkikgss6mv5g6s","image":{"cover":[{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_US.jpg","__typename":"URL"},"__typename":"Content","headline":"And they’re off. What could upend America’s election?","width":1280,"height":1684,"regionsAllowed":["US","CA","PM","UM","AI","BL","BQ","BV","CW","GS","MF","SX","AG","AR","AW","BS","BB","BZ","BM","BO","BR","KY","CL","CO","CR","CU","DM","DO","EC","SV","FK","GF","GD","GP","GT","GY","HN","HT","JM","MQ","MX","MS","NI","PA","PY","PE","PR","KN","LC","VC","SR","TT","TC","UY","VE","VG","VI"]}],"main":{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_US.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1684},"squareCover":[{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_SQ_US.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1280}],"__typename":"Media"}},{"url":{"canonical":"https://www.economist.com/a/printedition/2024-03-09","__typename":"URL"},"__typename":"Content","type":["PublicationIssue","RegionalIssue"],"headline":"WEEKLY EDITION: MAR 9TH 2024","description":"","subheadline":"","datePublished":"2024-03-09T00:00:00Z","datePublishedString":"Mar 9th 2024","id":"/content/b415k2h5cui7fcns2kuk381p7cr00si3","tegID":"b415k2h5cui7fcns2kuk381p7cr00si3","image":{"cover":[{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_EU.jpg","__typename":"URL"},"__typename":"Content","headline":"And they’re off. What could upend America’s election?","width":1280,"height":1684,"regionsAllowed":["AD","AL","AM","AX","AZ","BA","BG","BY","CH","CY","CZ","EE","FO","GE","GI","GL","HR","HU","IS","KG","KZ","LI","LT","LV","MC","MD","ME","MK","MT","NO","PL","RO","RS","RU","SI","SJ","SK","SM","TJ","TM","TR","UA","UZ","VA","IT","FR","ES","IE","AT","BE","DK","FI","DE","GR","LU","NL","PT","SE","BH","IR","IQ","IL","JO","KW","LB","OM","SA","SY","AE","PS","QA","YE","DZ","AO","BJ","BW","BF","BI","CM","CV","CF","TD","KM","CD","CI","DJ","EG","GQ","ER","ET","GA","GM","GH","GN","GW","KE","LS","LR","LY","MG","MU","MW","ML","MR","YT","MA","MZ","NA","NE","NG","RE","RW","SH","SS","ST","SN","SL","SO","ZA","SD","SZ","TZ","TG","TN","UG","EH","ZM","ZW","CG"]}],"main":{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_EU.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1684},"squareCover":[{"url":{"canonical":"https://www.economist.com/media-assets/image/20240309_DE_SQ_EU.jpg","__typename":"URL"},"__typename":"Content","width":1280,"height":1280}],"__typename":"Media"}}],"channel":{"tegID":"j53t6hsedat4l7rkbb1le98u73262sh5","__typename":"Content"},"_metadata":{"articleId":"/content/1um6f1d5i4t6deldkd9ma4gql52ftfa2","tegID":"1um6f1d5i4t6deldkd9ma4gql52ftfa2","title":"The real skinny - A frenzy of innovation in obesity drugs is under way | Leaders | The Economist","shareSnippet":"The real skinny – A frenzy of innovation in obesity drugs is under way","headline":"A frenzy of innovation in obesity drugs is under way","section":"Leaders","keywords":[],"author":["The Economist"],"url":"https://www.economist.com/leaders/2024/03/07/a-frenzy-of-innovation-in-obesity-drugs-is-under-way","type":"Article","articleBody":"","description":"Novo Nordisk and Eli Lilly are printing money now. But they will not be a stagnant duopoly","ogDescription":"Novo Nordisk and Eli Lilly are printing money now. But they will not be a stagnant duopoly","imageUrl":"https://www.economist.com/media-assets/image/20240309_LDD002.jpg","imageHeight":720,"imageWidth":1280,"datePublished":"2024-03-07T14:15:46Z","dateModified":"2024-03-07T22:29:27Z","dateCreated":"2024-03-06T11:41:55Z","isPrintArticle":true,"printEdition":"2024-03-09T00:00:00Z","copyrightYear":2024,"dateline":"","inLanguage":"en","interactive":false,"scripts":[],"css":[]},"sectionArticles":[{"id":"/content/qpdv8eb2h88475llth416pofo57og2sp","publication":[{"id":"/content/ndld7fhnv12a94rdb4elsi90p935h1jf","context":{"position":200.1,"__typename":"Content"},"__typename":"Content"},{"id":"/content/23j7i6b019gq99n60p77r1k56hm0jp0c","context":{"position":200.1,"__typename":"Content"},"__typename":"Content"},{"id":"/content/lvqsf1s86hc9obrhctvrb0d68a5377d7","context":{"position":200.1,"__typename":"Content"},"__typename":"Content"},{"id":"/content/s91ah9uegdq8v3q1i78ohfu88ntmculi","context":{"position":200.1,"__typename":"Content"},"__typename":"Content"},{"id":"/content/3so95mfk1putcqd9uf6offvhoba3k29e","context":{"position":200.1,"__typename":"Content"},"__typename":"Content"},{"id":"/content/dvsjeap731lsv61lg7oj3fpol5pb2ujh","context":{"position":200.1,"__typename":"Content"},"__typename":"Content"},{"id":"/content/9fe6gsio9nuviqsqgonkikgss6mv5g6s","context":{"position":200.1,"__typename":"Content"},"__typename":"Content"},{"id":"/content/b415k2h5cui7fcns2kuk381p7cr00si3","context":{"position":200.1,"__typename":"Content"},"__typename":"Content"}],"headline":"How to fix the Ivy League","url":{"canonical":"https://www.economist.com/leaders/2024/03/07/how-to-fix-the-ivy-league","__typename":"URL"},"__typename":"Content"},{"id":"/content/1um6f1d5i4t6deldkd9ma4gql52ftfa2","publication":[{"id":"/content/ndld7fhnv12a94rdb4elsi90p935h1jf","context":{"position":200.11,"__typename":"Content"},"__typename":"Content"},{"id":"/content/23j7i6b019gq99n60p77r1k56hm0jp0c","context":{"position":200.11,"__typename":"Content"},"__typename":"Content"},{"id":"/content/lvqsf1s86hc9obrhctvrb0d68a5377d7","context":{"position":200.11,"__typename":"Content"},"__typename":"Content"},{"id":"/content/s91ah9uegdq8v3q1i78ohfu88ntmculi","context":{"position":200.11,"__typename":"Content"},"__typename":"Content"},{"id":"/content/3so95mfk1putcqd9uf6offvhoba3k29e","context":{"position":200.11,"__typename":"Content"},"__typename":"Content"},{"id":"/content/dvsjeap731lsv61lg7oj3fpol5pb2ujh","context":{"position":200.11,"__typename":"Content"},"__typename":"Content"},{"id":"/content/9fe6gsio9nuviqsqgonkikgss6mv5g6s","context":{"position":200.11,"__typename":"Content"},"__typename":"Content"},{"id":"/content/b415k2h5cui7fcns2kuk381p7cr00si3","context":{"position":200.11,"__typename":"Content"},"__typename":"Content"}],"headline":"A frenzy of innovation in obesity drugs is under way","url":{"canonical":"https://www.economist.com/leaders/2024/03/07/a-frenzy-of-innovation-in-obesity-drugs-is-under-way","__typename":"URL"},"__typename":"Content"},{"id":"/content/pjnov0aulirars6bj94fb8g53tp82r7n","publication":[{"id":"/content/ndld7fhnv12a94rdb4elsi90p935h1jf","context":{"position":200.07,"__typename":"Content"},"__typename":"Content"},{"id":"/content/23j7i6b019gq99n60p77r1k56hm0jp0c","context":{"position":200.07,"__typename":"Content"},"__typename":"Content"},{"id":"/content/lvqsf1s86hc9obrhctvrb0d68a5377d7","context":{"position":200.07,"__typename":"Content"},"__typename":"Content"},{"id":"/content/s91ah9uegdq8v3q1i78ohfu88ntmculi","context":{"position":200.07,"__typename":"Content"},"__typename":"Content"},{"id":"/content/3so95mfk1putcqd9uf6offvhoba3k29e","context":{"position":200.07,"__typename":"Content"},"__typename":"Content"},{"id":"/content/dvsjeap731lsv61lg7oj3fpol5pb2ujh","context":{"position":200.07,"__typename":"Content"},"__typename":"Content"},{"id":"/content/9fe6gsio9nuviqsqgonkikgss6mv5g6s","context":{"position":200.07,"__typename":"Content"},"__typename":"Content"},{"id":"/content/b415k2h5cui7fcns2kuk381p7cr00si3","context":{"position":200.07,"__typename":"Content"},"__typename":"Content"}],"headline":"Three big risks that might tip America’s presidential election","url":{"canonical":"https://www.economist.com/leaders/2024/03/07/three-big-risks-that-might-tip-americas-presidential-election","__typename":"URL"},"__typename":"Content"},{"id":"/content/qj3dgelcejlfm5ridms4lr472s6fgb05","publication":[{"id":"/content/ndld7fhnv12a94rdb4elsi90p935h1jf","context":{"position":200.09,"__typename":"Content"},"__typename":"Content"},{"id":"/content/23j7i6b019gq99n60p77r1k56hm0jp0c","context":{"position":200.09,"__typename":"Content"},"__typename":"Content"},{"id":"/content/lvqsf1s86hc9obrhctvrb0d68a5377d7","context":{"position":200.09,"__typename":"Content"},"__typename":"Content"},{"id":"/content/s91ah9uegdq8v3q1i78ohfu88ntmculi","context":{"position":200.09,"__typename":"Content"},"__typename":"Content"},{"id":"/content/3so95mfk1putcqd9uf6offvhoba3k29e","context":{"position":200.09,"__typename":"Content"},"__typename":"Content"},{"id":"/content/dvsjeap731lsv61lg7oj3fpol5pb2ujh","context":{"position":200.09,"__typename":"Content"},"__typename":"Content"},{"id":"/content/9fe6gsio9nuviqsqgonkikgss6mv5g6s","context":{"position":200.09,"__typename":"Content"},"__typename":"Content"},{"id":"/content/b415k2h5cui7fcns2kuk381p7cr00si3","context":{"position":200.09,"__typename":"Content"},"__typename":"Content"}],"headline":"Britain’s budget cuts taxes on the promise of productivity gains","url":{"canonical":"https://www.economist.com/leaders/2024/03/06/britains-budget-cuts-taxes-on-the-promise-of-productivity-gains","__typename":"URL"},"__typename":"Content"},{"id":"/content/3r4cv269l8u8p03hed3lhvfa9c61ata9","publication":[{"id":"/content/ndld7fhnv12a94rdb4elsi90p935h1jf","context":{"position":200.08,"__typename":"Content"},"__typename":"Content"},{"id":"/content/23j7i6b019gq99n60p77r1k56hm0jp0c","context":{"position":200.08,"__typename":"Content"},"__typename":"Content"},{"id":"/content/lvqsf1s86hc9obrhctvrb0d68a5377d7","context":{"position":200.08,"__typename":"Content"},"__typename":"Content"},{"id":"/content/s91ah9uegdq8v3q1i78ohfu88ntmculi","context":{"position":200.08,"__typename":"Content"},"__typename":"Content"},{"id":"/content/3so95mfk1putcqd9uf6offvhoba3k29e","context":{"position":200.08,"__typename":"Content"},"__typename":"Content"},{"id":"/content/dvsjeap731lsv61lg7oj3fpol5pb2ujh","context":{"position":200.08,"__typename":"Content"},"__typename":"Content"},{"id":"/content/9fe6gsio9nuviqsqgonkikgss6mv5g6s","context":{"position":200.08,"__typename":"Content"},"__typename":"Content"},{"id":"/content/b415k2h5cui7fcns2kuk381p7cr00si3","context":{"position":200.08,"__typename":"Content"},"__typename":"Content"}],"headline":"Xi Jinping’s hunger for power is hurting China’s economy","url":{"canonical":"https://www.economist.com/leaders/2024/03/06/xi-jinpings-hunger-for-power-is-hurting-chinas-economy","__typename":"URL"},"__typename":"Content"}]},"cp2Content":{"id":"ed541b7d-a689-4c98-a050-3b4fd3f9f264","tegId":"1um6f1d5i4t6deldkd9ma4gql52ftfa2","brand":"ECONOMIST","contentIdentity":{"leadMediaType":"NONE","articleType":"OTHER","__typename":"ContentIdentity"},"section":{"id":"10922e8c-0f74-4fa4-9b56-01fe34953ffe","tegId":"0eqdc3kshoq96naup34ruco7pktc6n51","name":"Leaders","url":"https://www.economist.com/leaders/","__typename":"Section"},"authors":[],"headline":"A frenzy of innovation in obesity drugs is under way","rubric":"Novo Nordisk and Eli Lilly are printing money now. But they will not be a stagnant duopoly","flyTitle":"The real skinny ","url":"/leaders/2024/03/07/a-frenzy-of-innovation-in-obesity-drugs-is-under-way","leadComponent":{"type":"IMAGE","url":"https://www.economist.com/content-assets/images/20240309_LDD002.jpg","altText":null,"mode":"NORMAL","imageType":"ILLUSTRATION","caption":{"textHtml":"","__typename":"AnnotatedText"},"credit":"Ricardo Tomás","source":null,"width":1280,"height":720,"__typename":"ImageComponent"},"teaserImage":null,"dateFirstPublished":"2024-03-07T14:15:46.839Z","__typename":"Article","byline":null,"dateline":null,"layout":{"headerStyle":"STANDARD","__typename":"ArticleLayout"},"ads":{"channels":[{"score":"28217.996","name":"gv_safe","__typename":"ArticleAdsChannel"},{"score":"4.986","name":"gb_safe","__typename":"ArticleAdsChannel"},{"score":"4.986","name":"gb_safe_from_high","__typename":"ArticleAdsChannel"},{"score":"4.986","name":"gb_safe_from_high_med","__typename":"ArticleAdsChannel"},{"score":"4.986","name":"pos_israel-hamas_war","__typename":"ArticleAdsChannel"},{"score":"4.976","name":"gs_busfin","__typename":"ArticleAdsChannel"},{"score":"4.846","name":"gs_health","__typename":"ArticleAdsChannel"},{"score":"4.846","name":"neg_goldmansachs_brandsafety","__typename":"ArticleAdsChannel"},{"score":"4.844","name":"healthcare_related_topics","__typename":"ArticleAdsChannel"},{"score":"3.252","name":"chanel_neg","__typename":"ArticleAdsChannel"},{"score":"3.208","name":"gs_health_misc","__typename":"ArticleAdsChannel"},{"score":"2.53","name":"gs_busfin_indus","__typename":"ArticleAdsChannel"},{"score":"2.304","name":"neg_omd_exclusion","__typename":"ArticleAdsChannel"},{"score":"2.191","name":"future_of_work_test","__typename":"ArticleAdsChannel"},{"score":"2.135","name":"neg_exxon","__typename":"ArticleAdsChannel"},{"score":"2.068","name":"gs_healthylvng","__typename":"ArticleAdsChannel"},{"score":"1.983","name":"healthcare","__typename":"ArticleAdsChannel"},{"score":"1.942","name":"america_department_commerce","__typename":"ArticleAdsChannel"},{"score":"1.867","name":"gs_business","__typename":"ArticleAdsChannel"},{"score":"1.778","name":"neg_dit4","__typename":"ArticleAdsChannel"},{"score":"1.762","name":"test","__typename":"ArticleAdsChannel"},{"score":"1.663","name":"ibm_blacklist","__typename":"ArticleAdsChannel"},{"score":"1.618","name":"neg_fidelity_gmo","__typename":"ArticleAdsChannel"},{"score":"1.574","name":"gs_busfin_economy","__typename":"ArticleAdsChannel"},{"score":"1.532","name":"ssga_currency_wars","__typename":"ArticleAdsChannel"},{"score":"1.408","name":"fow_barclays","__typename":"ArticleAdsChannel"},{"score":"1.389","name":"cigna_healthyhybridworkplace","__typename":"ArticleAdsChannel"},{"score":"1.375","name":"neg_3166_vca_brand-safety","__typename":"ArticleAdsChannel"},{"score":"1.367","name":"america_department_health","__typename":"ArticleAdsChannel"},{"score":"1.347","name":"gs_health_weightloss","__typename":"ArticleAdsChannel"},{"score":"1.347","name":"gs_healthylvng_weightloss","__typename":"ArticleAdsChannel"},{"score":"1.324","name":"neg_workday_master","__typename":"ArticleAdsChannel"},{"score":"1.312","name":"microsoft_blacklist","__typename":"ArticleAdsChannel"},{"score":"1.241","name":"gs_economy","__typename":"ArticleAdsChannel"},{"score":"1.166","name":"neg_jpm_2024q4","__typename":"ArticleAdsChannel"},{"score":"1.165","name":"gt_mixed","__typename":"ArticleAdsChannel"},{"score":"1.139","name":"business_startup","__typename":"ArticleAdsChannel"},{"score":"1.134","name":"neg_3166_vca_brand-safety3","__typename":"ArticleAdsChannel"},{"score":"1.09","name":"gs_tech","__typename":"ArticleAdsChannel"},{"score":"1.085","name":"neg_dit","__typename":"ArticleAdsChannel"},{"score":"1.079","name":"future_of_work","__typename":"ArticleAdsChannel"},{"score":"1.029","name":"barclays_contextual_targets_2022-08-22","__typename":"ArticleAdsChannel"},{"score":"1.024","name":"ssga_infrastructure","__typename":"ArticleAdsChannel"},{"score":"1.014","name":"gs_busfin_economy_markets","__typename":"ArticleAdsChannel"},{"score":"1.014","name":"gs_economy_markets","__typename":"ArticleAdsChannel"},{"score":"0.989","name":"artificial_intelligence","__typename":"ArticleAdsChannel"},{"score":"0.982","name":"america_medicare","__typename":"ArticleAdsChannel"},{"score":"0.916","name":"ts_tech","__typename":"ArticleAdsChannel"},{"score":"0.893","name":"fidelity_blacklist","__typename":"ArticleAdsChannel"},{"score":"0.891","name":"universal_negative_keywords","__typename":"ArticleAdsChannel"},{"score":"0.872","name":"cigna_puttingfamilyfirst","__typename":"ArticleAdsChannel"},{"score":"0.871","name":"gs_busfin_business","__typename":"ArticleAdsChannel"},{"score":"0.862","name":"ibm_tech_2020","__typename":"ArticleAdsChannel"}],"__typename":"ArticleAds"},"dateModified":"2024-03-07T22:29:44.436Z","dateCreated":"2024-03-07T14:15:57.555Z","datePublished":"2024-03-07T22:29:27.000Z","dateRevised":null,"body":[{"type":"PARAGRAPH","text":"Weight-loss jabs have turned out to be blockbusters. And for good reason. For one thing, after centuries of false promises and quackery, these drugs actually work. With nearly half the world’s population expected to be obese or overweight by 2030, demand for them is assured. And, more excitingly, they may be approved for a broader set of uses. Clinical trials suggest that they could reduce the risk of heart attacks, kidney disease and perhaps even Alzheimer’s. By the end of the decade annual sales of obesity medicines could hit $80bn, making them one of pharma’s biggest classes of drugs.","textHtml":"\u003cspan data-caps=\"initial\"\u003eW\u003c/span\u003e\u003csmall\u003eeight-loss jabs\u003c/small\u003e have turned out to be blockbusters. And for good reason. For one thing, after centuries of false promises and quackery, these drugs actually work. With nearly half the world’s population expected to be obese or overweight by 2030, demand for them is assured. And, more excitingly, they may be approved for a broader set of uses. Clinical trials suggest that they could reduce the risk of heart attacks, kidney disease and perhaps even Alzheimer’s. By the end of the decade \u003ca href=\"https://www.economist.com/business/2024/03/04/the-battle-over-the-trillion-dollar-weight-loss-bonanza\"  rel=\"nofollow\"\u003eannual sales of obesity medicines\u003c/a\u003e could hit $80bn, making them one of pharma’s biggest classes of drugs.","__typename":"ParagraphComponent"},{"type":"PARAGRAPH","text":"No wonder enthusiasm for the makers of these drugs, Novo Nordisk and Eli Lilly, is at fever pitch. Since the start of 2023 Novo, maker of Wegovy (and its sibling Ozempic), has seen its market capitalisation soar by 87% to $560bn, making it Europe’s most valuable company. Meanwhile the market value of Lilly, maker of Zepbound (and its sibling Mounjaro), has more than doubled to $740bn. One of these drugmakers could be the first to attain a market value of a trillion dollars, joining an elite club mostly made up of tech firms.","textHtml":"No wonder enthusiasm for the makers of these drugs, Novo Nordisk and Eli Lilly, is at fever pitch. Since the start of 2023 Novo, maker of Wegovy (and its sibling Ozempic), has seen its market capitalisation soar by 87% to $560bn, making it Europe’s most valuable company. Meanwhile the market value of Lilly, maker of Zepbound (and its sibling Mounjaro), has more than doubled to $740bn. One of these drugmakers could be the first to attain a market value of a trillion dollars, joining an elite club mostly made up of tech firms.","__typename":"ParagraphComponent"},{"type":"IMAGE","url":"https://www.economist.com/content-assets/images/20240309_LDC677.png","altText":null,"mode":"SLIM","imageType":"CHART","caption":{"textHtml":"","__typename":"AnnotatedText"},"credit":"The Economist","source":null,"width":608,"height":626,"__typename":"ImageComponent"},{"type":"PARAGRAPH","text":"Add in the limited volumes and high prices for these drugs today, and you might think that this nascent industry is on course to be a price-gouging duopoly. In fact, the market will soon look drastically different from what you see now.","textHtml":"Add in the limited volumes and high prices for these drugs today, and you might think that this nascent industry is on course to be a price-gouging duopoly. In fact, the market will soon look drastically different from what you see now.","__typename":"ParagraphComponent"},{"type":"PARAGRAPH","text":"Right now the drugs are in short supply. Shortages of their active ingredients, like semaglutide for Wegovy, and of the skinny “pens” used to inject the medicine, are a constraint on production. And with a list price of almost $16,000 a year, these treatments are not cheap. Although a few users may be able to afford the cost themselves, most will need help from insurers or health services—many of which have yet to be convinced that the benefits are worth the drugs’ eye-watering prices.","textHtml":"Right now the drugs are in short supply. Shortages of their active ingredients, like semaglutide for Wegovy, and of the skinny “pens” used to inject the medicine, are a constraint on production. And with a list price of almost $16,000 a year, these treatments are not cheap. Although a few users may be able to afford the cost themselves, most will need help from insurers or health services—many of which have yet to be convinced that the benefits are worth the drugs’ eye-watering prices.","__typename":"ParagraphComponent"},{"type":"PARAGRAPH","text":"Access will be an even bigger problem in much of the emerging world, which is projected to experience the largest increases in obesity as incomes rise and diets change. So far most of Lilly’s and Novo’s sales have been in America, with the rest going mainly to Europe. Nor does it help emerging-world patients that the jabs need to be refrigerated, making them unsuitable for use in countries with less developed supply chains.","textHtml":"Access will be an even bigger problem in much of the emerging world, which is projected to experience the largest increases in obesity as incomes rise and diets change. So far most of Lilly’s and Novo’s sales have been in America, with the rest going mainly to Europe. Nor does it help emerging-world patients that the jabs need to be refrigerated, making them unsuitable for use in countries with less developed supply chains.","__typename":"ParagraphComponent"},{"type":"PARAGRAPH","text":"Yet there are good reasons to think that in future the market will see expanded supply, lower prices and a more global patient base. For a start, investment by Lilly and Novo to expand production should ease bottlenecks over time. Both firms are pouring billions of dollars into boosting supply by building their own capacity and teaming up with other manufacturers. Lilly and Novo are also racing to gain an edge over each other. Novo has already developed a pill that is about as effective as its injectable version. Lilly expects to launch its own obesity pill in a few years. Both companies also have newer versions of the drugs in the late stages of development which are more efficacious or have fewer side-effects.","textHtml":"Yet there are good reasons to think that in future the market will see expanded supply, lower prices and a more global patient base. For a start, investment by Lilly and Novo to expand production should ease bottlenecks over time. Both firms are pouring billions of dollars into boosting supply by building their own capacity and teaming up with other manufacturers. Lilly and Novo are also racing to gain an edge over each other. Novo has already developed a pill that is about as effective as its injectable version. Lilly expects to launch its own obesity pill in a few years. Both companies also have newer versions of the drugs in the late stages of development which are more efficacious or have fewer side-effects.","__typename":"ParagraphComponent"},{"type":"PARAGRAPH","text":"More important in the long term, however, is the array of competitors preparing to enter the market. Wegovy, Zepbound and their ilk are less protected by patents than, say, Humira, a blockbuster anti-inflammatory drug that has reaped more than $200bn in sales over 20 years.","textHtml":"More important in the long term, however, is the array of competitors preparing to enter the market. Wegovy, Zepbound and their ilk are less protected by patents than, say, Humira, a blockbuster anti-inflammatory drug that has reaped more than $200bn in sales over 20 years.","__typename":"ParagraphComponent"},{"type":"PARAGRAPH","text":"Already more than 70 companies are running close to 100 clinical trials for obesity drugs. These include big pharma firms (Amgen and Boehringer Ingelheim) and smaller biotechs (Viking Therapeutics and Structure Therapeutics) in the West, as well as Chinese drugmakers such as Sciwind Biosciences and Eccogene. Many are testing versions that are distinct enough from Wegovy and Zepbound that patent protections will not apply, allowing them to come to market within a few years, should they gain regulators’ blessing.","textHtml":"Already more than 70 companies are running close to 100 clinical trials for obesity drugs. These include big pharma firms (Amgen and Boehringer Ingelheim) and smaller biotechs (Viking Therapeutics and Structure Therapeutics) in the West, as well as Chinese drugmakers such as Sciwind Biosciences and Eccogene. Many are testing versions that are distinct enough from Wegovy and Zepbound that patent protections will not apply, allowing them to come to market within a few years, should they gain regulators’ blessing.","__typename":"ParagraphComponent"},{"type":"PARAGRAPH","text":"Some candidates in the pipeline could be more effective than existing treatments; others might do away with the inconvenience of today’s drugs, which require patients to inject themselves once a week and to continue taking them indefinitely to keep their weight down. Viking’s experimental drug, for example, has been shown to help patients shed more weight than existing jabs. Amgen is testing a treatment that does not require patients to be on the drugs indefinitely. And Structure is developing a promising-looking pill.","textHtml":"Some candidates in the pipeline could be more effective than existing treatments; others might do away with the inconvenience of today’s drugs, which require patients to inject themselves once a week and to continue taking them indefinitely to keep their weight down. Viking’s experimental drug, for example, has been shown to help patients shed more weight than existing jabs. Amgen is testing a treatment that does not require patients to be on the drugs indefinitely. And Structure is developing a promising-looking pill.","__typename":"ParagraphComponent"},{"type":"CROSSHEAD","text":"Healthy competition ","__typename":"CrossheadComponent"},{"type":"PARAGRAPH","text":"This frenzy of innovation is welcome. Lilly and Novo may lose their lead in the long term if cheaper alternatives arise; or they may themselves furiously innovate to reduce costs. Either way, prices should come down, making the drugs more accessible to patients around the world. Today the two pharma firms are reaping the rewards from their blockbuster drugs. But in time it will be consumers who benefit most of all. ■","textHtml":"This frenzy of innovation is welcome. Lilly and Novo may lose their lead in the long term if cheaper alternatives arise; or they may themselves furiously innovate to reduce costs. Either way, prices should come down, making the drugs more accessible to patients around the world. Today the two pharma firms are reaping the rewards from their blockbuster drugs. But in time it will be consumers who benefit most of all. \u003cspan class=\"ufinish\"\u003e■\u003c/span\u003e","__typename":"ParagraphComponent"}],"footer":[],"seo":{"title":null,"description":null,"__typename":"ArticleSEO"},"tags":[],"printHeadline":"The real skinny","printRubric":"Novo Nordisk and Eli Lilly are printing money now. But a wave of competition is coming ","printFlyTitle":"Obesity drugs ","edition":null},"featureFlags":["SF_SIGNPOSTING","SOURCEPOINT","ONBOARDING_NOTIFICATION","ONBOARDING_GROUP_NOTIFICATION","OPTIMIZELY_SELF_HOSTING","LAPSED_USER_NOTIFICATION","CP2_ARTICLE","REGISTRANT_ONBOARDING","APP_PROMO_PAGE","NEXT_SCRIPT_THIRD_PARTIES","PODCAST_SHOW_PROMO_LINK_WIB","SHOW_ARTICLE_UPDATED_DATE","SUMMER_EDITION_1843","TWA_HOMEPAGE","PODCAST_NATIVE_AUDIO_PLAYER","LOCKED_PODCASTS","TOPIC_PAGE","ARTICLE_TAGS","GROUP_SUBSCRIBER_WELCOME_MODAL","GROUP_ONE_TIME_COOKIE_BANNER","ACCESSIBLE_FOR_FREE","TYPE_QUERY_MIDDLEWARE","SINGLE_ARTICLE_ROUTE","SHOW_AI_SEARCH_CTA","CP2_ARTICLE_GQL","CP2_TOPIC_GQL"],"statusCode":200,"paywallCheck":{"shouldDropPaywall":false},"newsletters":{"newsletters":[{"code":"el_boletin","availableTo":["core"],"ident":"el-boletin","title":"El Boletín","frequency":"Weekly","imageUrl":"https://myaccount.economist.com/file-asset-public/El_Boletin?oid=00D3z000002JvyiEAC","tagline":"Subscriber only","slug":"el-boletin","hasPreview":false,"isNew":true,"description":"Follow the action in Latin America, from the depths of the Brazilian Amazon to the Mexican-American border","promo":{"title":"Stay informed with our weekly Latin America newsletter","description":"Every week our correspondents share insights on politics, economics and business from an increasingly complex region","tagline":"Subscriber only"},"keywords":["The Americas"],"priority":2,"isKeywordFallback":false,"onboardingPreSelect":false,"live":true},{"code":"us_in_brief","availableTo":["core"],"ident":"us-in-brief","title":"The US in brief","frequency":"Daily","imageUrl":"https://myaccount.economist.com/file-asset-public/US_in_brief?oid=00D3z000002JvyiEAC","tagline":"Subscriber only","slug":"us-in-brief","hasPreview":false,"isNew":true,"description":"A sharp round-up of the most important US political news","promo":{"title":"A sharp round-up of the most important US political news","description":"Sign up for updates from our correspondents and data journalists, poll tracker and election-forecast model as the 2024 race unfolds","tagline":"Subscriber only"},"keywords":["United States","United States Senate","Republican Party","Donald Trump","Joe Biden","Democratic Party","Executive Office of the President of the United States"],"priority":99,"isKeywordFallback":false,"onboardingPreSelect":false,"live":true},{"code":"cafe_europa","availableTo":["core"],"ident":"cafe-europa","title":"Café Europa","frequency":"Weekly","imageUrl":"https://myaccount.economist.com/file-asset-public/cafeeuropa?oid=00D3z000002JvyiEAC","tagline":"Subscriber only","slug":"cafe-europa","hasPreview":false,"isNew":false,"description":"Inside Europe, from the front lines in Ukraine to the corridors of power in Brussels","promo":{"title":"Stay informed with our weekly Europe newsletter","description":"Inside Europe, from the front lines in Ukraine to the corridors of power in Brussels","tagline":"Subscriber only"},"keywords":["Europe"],"priority":2,"isKeywordFallback":false,"onboardingPreSelect":false,"live":true},{"code":"essential_india","availableTo":["anonymous","registered","espresso","podcast","core"],"ident":"essential-india","title":"Essential India","frequency":"Weekly","imageUrl":"https://myaccount.economist.com/file-asset-public/essential_india?oid=00D3z000002JvyiEAC","slug":"essential-india","hasPreview":false,"isNew":false,"description":"Your guide to an emerging great power","promo":{"title":"Stay informed with our weekly India newsletter","description":"Understand a vast and complicated country that will increasingly shape the future","tagline":""},"keywords":["Asia"],"priority":2,"isKeywordFallback":false,"onboardingPreSelect":false,"live":true},{"code":"the_war_room","availableTo":["core"],"ident":"the-war-room","title":"The War Room","frequency":"Weekly","imageUrl":"https://myaccount.economist.com/file-asset-public/the_war_room?oid=00D3z000002JvyiEAC","tagline":"Subscriber only","slug":"the-war-room","hasPreview":true,"isNew":false,"description":"The best of \u003cem\u003eThe Economist\u003c/em\u003e’s defence coverage, in one place","promo":{"title":"","description":"","tagline":"Subscriber only"},"keywords":[],"priority":-1,"isKeywordFallback":false,"onboardingPreSelect":false,"live":true},{"code":"plot_twist","availableTo":["core"],"ident":"plot-twist","title":"Plot Twist","frequency":"Weekly","imageUrl":"https://myaccount.economist.com/file-asset-public/Plot_Twist?oid=00D3z000002JvyiEAC","tagline":"Subscriber only","slug":"plot-twist","hasPreview":true,"isNew":false,"description":"A weekly conversation about culture. Because culture is a serious business","promo":{"title":"Broaden your perspective with our weekly culture newsletter","description":"Exploring trends and connections across entertainment, the arts and politics","tagline":"Subscriber only"},"keywords":["Culture"],"priority":2,"isKeywordFallback":false,"onboardingPreSelect":false,"live":true},{"code":"blighty","availableTo":["core"],"ident":"blighty","title":"Blighty","frequency":"Weekly","imageUrl":"https://myaccount.economist.com/file-asset-public/Blighty?oid=00D3z000002JvyiEAC","tagline":"Subscriber only","slug":"blighty","hasPreview":true,"isNew":false,"description":"Analysing the challenges facing Britain and what needs to be done to overcome them","promo":{"title":"Stay informed with our weekly Britain newsletter","description":"Analysing the challenges facing Britain and what needs to be done to overcome them","tagline":"Subscriber only"},"keywords":["Britain"],"priority":2,"isKeywordFallback":false,"onboardingPreSelect":false,"live":true},{"code":"drum_tower","availableTo":["core"],"ident":"drum-tower","title":"Drum Tower","frequency":"Weekly","imageUrl":"https://myaccount.economist.com/file-asset-public/drumtower?oid=00D3z000002JvyiEAC","tagline":"Subscriber only","slug":"drum-tower","hasPreview":true,"isNew":false,"description":"Understand what the world makes of China—and what China makes of the world","promo":{"title":"Stay informed with our weekly China newsletter","description":"Understand what the world makes of China—and what China makes of the world","tagline":"Subscriber only"},"keywords":["China"],"priority":2,"isKeywordFallback":false,"onboardingPreSelect":false,"live":true},{"code":"the_bottom_line","availableTo":["core"],"ident":"the-bottom-line","title":"The Bottom Line","frequency":"Weekly","imageUrl":"https://myaccount.economist.com/file-asset-public/the_bottom_line?oid=00D3z000002JvyiEAC","tagline":"Subscriber only","slug":"the-bottom-line","hasPreview":true,"description":"Your essential guide to global business and technology","promo":{"title":"Need to track the megatrends shaping business and technology?","description":"From supply chains to semiconductors, The Bottom Line newsletter has you covered","tagline":"Subscriber only"},"keywords":["Business"],"priority":2,"isKeywordFallback":false,"onboardingPreSelect":false,"live":true},{"code":"espresso","availableTo":["espresso","core"],"ident":"the-world-in-brief","title":"The World in Brief","frequency":"Daily","imageUrl":"https://myaccount.economist.com/file-asset-public/the_world_in_brief?oid=00D3z000002JvyiEAC","tagline":"Subscriber only","slug":"the-world-in-brief","hasPreview":true,"description":"Catch up quickly on the global stories that matter","promo":{"title":"Catch up quickly on the stories that matter","description":"Sign up to enjoy a mind-expanding mix of stories, delivered six days a week","tagline":"Subscriber only"},"keywords":[],"priority":-1,"isKeywordFallback":false,"onboardingPreSelect":false,"live":true},{"code":"cover_story","availableTo":["core"],"ident":"cover-story","title":"Cover Story","frequency":"Weekly","imageUrl":"https://myaccount.economist.com/file-asset-public/Cover_Story?oid=00D3z000002JvyiEAC","tagline":"Subscriber only","slug":"cover-story","hasPreview":true,"description":"A behind-the-scenes look at how we chose and designed this week’s cover","promo":{"title":"How we chose this week’s cover image","description":"Delivered to your inbox every weekend","tagline":"Subscriber only"},"keywords":[],"priority":3,"isKeywordFallback":false,"onboardingPreSelect":true,"live":true},{"code":"checks_and_balance","availableTo":["core"],"ident":"checks-and-balance","title":"Checks and Balance","frequency":"Weekly","imageUrl":"https://myaccount.economist.com/file-asset-public/Checks_and_Balance?oid=00D3z000002JvyiEAC","tagline":"Subscriber only","slug":"checks-and-balance","hasPreview":true,"description":"Exclusive insight from our correspondents in America","promo":{"title":"Exclusive insight and reading recommendations from our correspondents in America","description":"Delivered to your inbox every week","tagline":"Subscriber only"},"keywords":["United States","United States Senate","Republican Party","Donald Trump","Joe Biden","Democratic Party","Executive Office of the President of the United States"],"priority":6,"isKeywordFallback":false,"onboardingPreSelect":false,"live":true},{"code":"simply_science","availableTo":["core"],"ident":"simply-science","title":"Simply Science","frequency":"Weekly","imageUrl":"https://myaccount.economist.com/file-asset-public/Simply_Science2?oid=00D3z000002JvyiEAC","tagline":"Subscriber only","slug":"simply-science","hasPreview":true,"description":"A weekly fix of our mind-expanding science coverage","promo":{"title":"Curious about the world? Enjoy a weekly fix of our mind-expanding science coverage","description":"Delivered to you every week","tagline":"Subscriber only"},"keywords":["science and technology","Science \u0026 technology","biology","astronomy","philosophy","chemistry","diseases and conditions","genetics","cancer","medicine","physics"],"priority":4,"isKeywordFallback":false,"onboardingPreSelect":false,"live":true},{"code":"climate_change","availableTo":["core"],"ident":"the-climate-issue","title":"The Climate Issue","frequency":"Fortnightly","imageUrl":"https://myaccount.economist.com/file-asset-public/Climate_issue?oid=00D3z000002JvyiEAC","tagline":"Subscriber only","slug":"the-climate-issue","hasPreview":true,"description":"Climate-change analysis that you won’t read elsewhere in \u003cem\u003eThe Economist\u003c/em\u003e","promo":{"title":"Climate-change analysis that you won’t read elsewhere in \u003cem\u003eThe Economist\u003c/em\u003e","description":"Delivered to your inbox every fortnight","tagline":"Subscriber only"},"keywords":["energy industry","migration of people","weather","energy and resource","plant","synthetic and plastic chemicals","forestry and timber","climate change","global warming","environment","environmental politics","environmental pollution"],"priority":5,"isKeywordFallback":false,"onboardingPreSelect":false,"live":true},{"code":"money_talks","availableTo":["core"],"ident":"money-talks","title":"Money Talks","frequency":"Weekly","imageUrl":"https://myaccount.economist.com/file-asset-public/money_talks?oid=00D3z000002JvyiEAC","tagline":"Subscriber only","slug":"money-talks","hasPreview":true,"description":"Expert analysis of the biggest stories in economics and markets","promo":{"title":"Expert analysis of the biggest stories in economics and markets","description":"Delivered to your inbox every week","tagline":"Subscriber only"},"keywords":["Finance \u0026 economics"],"priority":100,"isKeywordFallback":false,"onboardingPreSelect":false,"live":true},{"code":"off_the_charts","availableTo":["core"],"ident":"off-the-charts","title":"Off the Charts","frequency":"Weekly","imageUrl":"https://myaccount.economist.com/file-asset-public/Off_the_charts2?oid=00D3z000002JvyiEAC","tagline":"Subscriber only","slug":"off-the-charts","hasPreview":true,"description":"Taking you behind the scenes of our data journalism","promo":{"title":"Taking you behind the scenes of our data journalism","description":"Directly to your inbox every week","tagline":"Subscriber only"},"keywords":["Graphic detail"],"priority":99,"isKeywordFallback":false,"onboardingPreSelect":false,"live":true},{"code":"the_extraordinary_story","availableTo":["anonymous","registered","espresso","podcast","core"],"ident":"the-extraordinary-story","title":"The Extraordinary Story","frequency":"Weekly","imageUrl":"https://myaccount.economist.com/file-asset-public/the_extraordinary_story?oid=00D3z000002JvyiEAC","slug":"the-extraordinary-story","hasPreview":true,"description":"Long reads and life from \u003cem\u003e1843 magazine\u003c/em\u003e","promo":{"title":"Long reads and life from \u003cem\u003e1843 magazine\u003c/em\u003e","description":"Delivered to your inbox every weekend","tagline":""},"keywords":["1843 magazine"],"priority":100,"isKeywordFallback":false,"onboardingPreSelect":false,"live":true},{"code":"te_today","availableTo":["anonymous","registered","espresso","podcast","core"],"ident":"the-economist-today","title":"The Economist today","frequency":"Daily","imageUrl":"https://myaccount.economist.com/file-asset-public/The_Economist_Today?oid=00D3z000002JvyiEAC","slug":"the-economist-today","hasPreview":true,"description":"The very best of our journalism, handpicked for you each weekday","promo":{"title":"Handpicked stories, in your inbox","description":"A daily newsletter with the best of our journalism","tagline":""},"keywords":[],"priority":0,"isKeywordFallback":true,"onboardingPreSelect":false,"live":true},{"code":"te_this_week","availableTo":["anonymous","registered","espresso","podcast","core"],"ident":"the-economist-this-week","title":"The Economist this week","frequency":"Weekly","imageUrl":"https://myaccount.economist.com/file-asset-public/The_Economist_This_Week?oid=00D3z000002JvyiEAC","slug":"the-economist-this-week","hasPreview":true,"description":"Highlights from the latest weekly issue, introduced by our editor","promo":{"title":"Highlights from the latest weekly issue, introduced by our editor","description":"Directly to your inbox every week","tagline":""},"keywords":[],"priority":2,"isKeywordFallback":false,"onboardingPreSelect":true,"live":true}],"status":"ok"}},"__N_SSP":true},"page":"/[...slug]","query":{"slug":["leaders","2024","03","07","a-frenzy-of-innovation-in-obesity-drugs-is-under-way"]},"buildId":"A8nNoPAwwxn_WAzGhqKtt","assetPrefix":"/engassets","isFallback":false,"gssp":true,"scriptLoader":[]}